Reports Q1 revenue $119.126M, consensus $116.79M. "We are pleased to report another quarter of strong performance and operational excellence across our business. We saw continued momentum in our commercial business for WAKIX, as well as in the advancement of our clinical development programs for pitolisant," stated Jeffrey M. Dayno, M.D., President and Chief Executive Officer of Harmony. "WAKIX commercial performance reflects its unique and meaningfully differentiated product profile, allowing us to reach an important milestone of surpassing $1 billion in cumulative net revenue within the first three and half years since launch, one of the most successful launches ever for a rare disease company. We have demonstrated strong and continued growth since the launch of WAKIX and remain a growth story, given the vast opportunity that remains in the narcolepsy market, the potential of our current life cycle management programs, new formulations of pitolisant that are being developed, and growth through business development."
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on HRMY:
- Harmony Biosciences Reports First Quarter 2023 Financial Results and Business Updates
- 3 “Strong Buy” Stocks With Short Squeeze Potential
- HRMY Upcoming Earnings Report: What to Expect?
- Harmony Biosciences names Jeffrey Dayno, M.D as CEO
- BofA starts Harmony Biosciences at Neutral, sees downside risk to consensus